Pharmacogenomics of Tamoxifen and Irinotecan Therapies

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 553-567

  Algeciras Schimnich, Alicia ^a   O'Kane, Dennis J ^a   Snozek, Christine L H ^a  

^a Department of Health Sciences Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTHRACYCLINE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; ENZYME INHIBITOR; ESTROGEN RECEPTOR; FLUOROURACIL; FLUOXETINE; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; NORTAMOXIFEN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ALLELE; BREAST CANCER; COLORECTAL CANCER; DIAPHORESIS; DIARRHEA; DRUG METABOLISM; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HOT FLUSH; HUMAN; LACRIMATION DISORDER; NEUTROPENIA; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TAMOXIFEN; TREATMENT OUTCOME;

EID: 57149085290     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.05.004     Document Type: Review

References (69)

1. Package insert for irinotecan as available on the FDA website. http://www.fda.gov/ Available at:Accessed March 3, 2008
2. US clinical trials registry. http://clinicaltrials.gov/ Available at:Accessed March 3, 2008
3. Wierdl M., Tsurkan L., Hyatt J.L., et al. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther 15 3 (2008) 183-192
4. Hanioka N., Ozawa S., Jinno H., et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 30 4 (2002) 391-396
5. McLeod H.L., and Watters J.W. Irinotecan pharmacogenetics: is it time to intervene?. J Clin Oncol 22 8 (2004) 1356-1359
6. *28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47 1 (2007) 78-86
7. Kim T.W., and Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 29 3 (2007) 265-270
8. Nagar S., and Remmel R.P. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25 11 (2006) 1659-1672
9. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 8 (2004) 1382-1388
10. Innocenti F., and Ratain M.J. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7 8 (2006) 1211-1221
11. O'Dwyer P.J., and Catalano R.B. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24 28 (2006) 4534-4538
12. Haga S.B., Thummel K.E., and Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 16 12 (2006) 847-854
13. *27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 9 3 (2007) 258-262
14. *)6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 261 2 (2008) 165-171
15. Jinno H., Tanaka-Kagawa T., Hanioka N., et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31 1 (2003) 108-113
16. Gagne J.F., Montminy V., Belanger P., et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62 3 (2002) 608-617
17. *28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99 17 (2007) 1290-1295
18. Stewart C.F., Panetta J.C., O'Shaughnessy M.A., et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25 18 (2007) 2594-2600
19. Bomgaars L.R., Bernstein M., Krailo M., et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25 29 (2007) 4622-4627
20. Rodriguez J., Zarate R., Bandres E., et al. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 13 44 (2007) 5867-5876
21. Cummings J., Ethell B.T., Jardine L., et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63 23 (2003) 8443-8450
22. Innocenti F., Vokes E.E., and Ratain M.J. Irinogenetics: what is the right star?. J Clin Oncol 24 15 (2006) 2221-2224
23. Villeneuve L., Girard H., Fortier L.C., et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307 1 (2003) 117-128
24. Paoluzzi L., Singh A.S., Price D.K., et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44 8 (2004) 854-860
25. Ando M., Ando Y., Sekido Y., et al. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93 5 (2002) 591-597
26. Carlini L.E., Meropol N.J., Bever J., et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11 3 (2005) 1226-1236
27. *6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60 4 (2007) 515-522
28. Baudhuin L.M., Highsmith W.E., Skierka J., et al. Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism. Clin Biochem 40 9-10 (2007) 710-717
29. Huang C.K., Dulau A., Su-Rick C.J., et al. Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter. Diagn Mol Pathol 16 1 (2007) 50-53
30. Araki K., Fujita K., Ando Y., et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97 11 (2006) 1255-1259
31. Ramsay E.C., Anantha M., Zastre J., et al. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res 14 4 (2008) 1208-1217
32. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
33. Colleoni M., Gelber S., Goldhirsch A., et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24 9 (2006) 1332-1341
34. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
35. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 339 22 (1998) 1609-1618
36. Jordan V.C., Collins M.M., Rowsby L., et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75 2 (1977) 305-316
37. Lien E.A., Solheim E., Lea O.A., et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49 8 (1989) 2175-2183
38. Crewe H.K., Notley L.M., Wunsch R.M., et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30 8 (2000) 869-874
39. Stearns V., Beebe K.L., Iyengar M., et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289 21 (2003) 2827-2834
40. Desta Z., Ward B.A., Soukhova N.V., et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310 3 (2004) 1062-1075
41. Coller J.K., Krebsfaenger N., Klein K., et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54 2 (2002) 157-167
42. Borgna J.L., and Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biolumin Chemilumin 256 2 (1981) 859-868
43. Robertson D.W., Katzenellenbogen J.A., Long D.J., et al. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16 1 (1982) 1-13
44. Coezy E., Borgna J.L., and Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42 1 (1982) 317-323
45. Johnson M.D., Zuo H., Lee K.H., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85 2 (2004) 151-159
46. Lim Y.C., Desta Z., Flockhart D.A., et al. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55 5 (2005) 471-478
47. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 21 (2005) 2211-2221
48. Ingelman-Sundberg M., Sim S.C., Gomez A., et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116 3 (2007) 496-526
49. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 1 (2005) 30-39
50. Borges S., Desta Z., Li L., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 1 (2006) 61-74
51. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 36 (2005) 9312-9318
52. Bonanni B., Macis D., Maisonneuve P., et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24 22 (2006) 3708-3709 [author reply: 3709]
53. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 3 (2005) 249-258
54. Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 1 (2007) R7
55. Wegman P., Vainikka L., Stal O., et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7 3 (2005) R284-R290
56. Goetz M.P., Kamal A., and Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83 1 (2008) 160-166
57. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 1 (2007) 113-121
58. Loibl S., Schwedler K., von Minckwitz G., et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - a double-blind, randomized study. Ann Oncol 18 4 (2007) 689-693
59. Young D. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling. Am J Health Syst Pharm 63 23 (2006) 2286-2296
60. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
61. Bevers T.B. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 7 16 (2006) 2301-2307
62. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295 23 (2006) 2727-2741
63. Tucker A.N., Tkaczuk K.A., Lewis L.M., et al. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 217 1 (2005) 61-72
64. Koch I., Weil R., Wolbold R., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 10 (2002) 1108-1114
65. Westlind-Johnsson A., Malmebo S., Johansson A., et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31 6 (2003) 755-761
66. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 33 (2007) 5187-5193
67. Chen G., Yin S., Maiti S., et al. 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16 6 (2002) 279-285
68. Nowell S., Sweeney C., Winters M., et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94 21 (2002) 1635-1640
69. Gjerde J., Hauglid M., Breilid H., et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19 1 (2008) 56-61